Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Specimen Handling 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × tinostamustine × Dermatologic × Clear all
NCT02576496 2024-07-25

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Mundipharma Research Limited

Phase 1 Completed
106 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Multiple Myeloma, Lymphoma, T-Cell, Cutaneous, Hematologic Neoplasms

NCT03903458 2019-04-08

ENIgMA

Cantonal Hospital of St. Gallen

Phase 1 Unknown
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡